Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtronic draws subpoena

This article was originally published in The Gray Sheet

Executive Summary

Documents relating to the firm's cardiac rhythm management devices are subpoenaed by the Office of Inspector General for the Department of Health and Human Services in the district of California, Medtronic discloses in a quarterly financial report filed Dec. 9 with the Securities and Exchange Commission. Related documents include "revenue, sales, marketing and promotional documents, documents relating to reimbursement communications to customers pertaining to the devices, documents relating to scientific studies and registries pertaining to the devices, and documents relating to payments or items of value provided to customers," Medtronic explains. The firm says it will comply with the subpoena, which it received on Sept. 16. Medtronic received a separate subpoena in June from the New Jersey attorney general's office as part of an investigation into industry ties to clinical trial investigators (1"The Gray Sheet" Aug. 10, 2009)

You may also be interested in...



New Jersey AG's Targets: J&J/DePuy, Biomet, Stryker, Medtronic And...

Johnson & Johnson/DePuy is the latest of four orthopedic device makers to acknowledge receipt of a subpoena from the New Jersey attorney general's office as part of an investigation into industry ties to clinical trial investigators

Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time

Small sterilizers told Medtech Insight that they were ready for the EPA’s controversial EtO emissions rule, while community advocates expressed concerns.

Day One Springs Into Commercial Action With Ojemda Approval

The company is targeting around 200 centers that treat the vast majority of the few thousand pediatric low-grade glioma patients who are candidates for the RAF-targeting drug.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT028275

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel